These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 17176363)

  • 1. Role of follow-on drugs and indications on the WHO Essential Drug List.
    Cohen J; Cabanilla L; Sosnov J
    J Clin Pharm Ther; 2006 Dec; 31(6):585-92. PubMed ID: 17176363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.
    DiMasi JA
    Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measuring progress in neglected disease drug development.
    Cohen JP; Sturgeon G; Cohen A
    Clin Ther; 2014 Jul; 36(7):1037-42. PubMed ID: 24906971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lost in translation: differences in antimicrobial indication approval policies between the United States and Europe.
    Pappas G; Ierodiakonou V; Falagas ME
    Clin Ther; 2009 Jul; 31(7):1595-603. PubMed ID: 19695409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FDA drug classification system.
    Sanborn MD; Godwin HN; Pessetto JD
    Am J Hosp Pharm; 1991 Dec; 48(12):2659-62. PubMed ID: 1814217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality medicines for the poor: experience of the Delhi programme on rational use of drugs.
    Chaudhury RR; Parameswar R; Gupta U; Sharma S; Tekur U; Bapna JS
    Health Policy Plan; 2005 Mar; 20(2):124-36. PubMed ID: 15746221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Essential drugs programmes in Africa.
    Laing R
    Afr Health; 1991 Nov; 14(1):32-3. PubMed ID: 12343453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Managing the expanded use of biologics across therapeutic areas: an example from b-cell targeted therapies.
    Cohen M; Morrow T; Penna P
    Am J Manag Care; 2006 Mar; 12(2 Suppl):S24-37; quiz S38. PubMed ID: 16551202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of essential drugs. Seventh report of the WHO Expert Committee.
    World Health Organ Tech Rep Ser; 1997; 867():1-74. PubMed ID: 9299932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations.
    Pinheiro Edos S; Antunes OA; Fortunak JM
    Antiviral Res; 2008 Sep; 79(3):143-65. PubMed ID: 18571246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigational drug tracking: Phases I-III and NDA submissions--Part I.
    Grant KL
    Hosp Pharm; 1994 Sep; 29(9):830-6, 839-44, 847-52 passim. PubMed ID: 10137064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of essential drugs. Eighth report of the WHO Expert Committee (including the revised Model List of Essential Drugs).
    World Health Organ Tech Rep Ser; 1998; 882():1-77. PubMed ID: 9922706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The history and contemporary challenges of the US Food and Drug Administration.
    Borchers AT; Hagie F; Keen CL; Gershwin ME
    Clin Ther; 2007 Jan; 29(1):1-16. PubMed ID: 17379043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Classification of orally administered drugs on the World Health Organization Model list of Essential Medicines according to the biopharmaceutics classification system.
    Lindenberg M; Kopp S; Dressman JB
    Eur J Pharm Biopharm; 2004 Sep; 58(2):265-78. PubMed ID: 15296954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of new drug availability in Canada and the United States and potential therapeutic implications of differences.
    Lexchin J
    Health Policy; 2006 Dec; 79(2-3):214-20. PubMed ID: 16472888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New drug approval times and 'therapeutic potential' in Canada, Australia, Sweden and the United States during the period 1992 to 1998.
    Rawson NS; Kaitin KI
    Can J Clin Pharmacol; 2000; 7(2):97-101. PubMed ID: 10958705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug policy in Nicaragua, between need-oriented activities and aggression.
    Laporte JR; Tognoni G
    Dev Dialogue; 1985; (2):121-8. PubMed ID: 12341044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economics of new oncology drug development.
    DiMasi JA; Grabowski HG
    J Clin Oncol; 2007 Jan; 25(2):209-16. PubMed ID: 17210942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How to anticipate the assessment of the public health benefit of new medicines?
    Massol J; Puech A; Boissel JP;
    Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.